PSTV Plus Therapeutics, Inc

2.57
-0.14  -5%
Previous Close 2.71
Open 2.66
Price To Book 64.16
Market Cap 9,677,214
Shares 3,770,588
Volume 115,936
Short Ratio
Av. Daily Volume 393,362
Stock charts supplied by TradingView

NewsSee all news

  1. Plus Therapeutics Shareholder Update: Transition Achieved in 2019; Poised for Expansion in 2020

    AUSTIN, Texas, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company") today issued the following Letter to Shareholders from Dr. Marc Hedrick, President and Chief Executive Officer.

  2. Plus Therapeutics Appoints Dr. An van Es-Johansson to Board of Directors

    AUSTIN, Texas, Jan. 02, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), today announced that Dr. An van Es-Johansson has joined the Company's Board of Directors to serve as an

  3. Plus Therapeutics to Present at Biotech Showcase 2020

    AUSTIN, Texas, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company") today announced that it has scheduled a company presentation at Biotech Showcase 2020, to be held January 13-15,

  4. Plus Therapeutics to Present at the LD Micro Main Event (XII)

    AUSTIN, Texas, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company") today announced that it will be participating at the upcoming 12th annual LD Micro Main Event.  Dr. Marc Hedrick,

  5. Plus Therapeutics Reports Third Quarter 2019 Financial and Business Results

    AUSTIN, Texas, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company") today announced financial and business results for the third quarter of 2019. Third quarter 2019 net income

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 trial to be initiated 2H 2020.
DocePLUS (ATI-1123)
Platinum-sensitive small cell lung cancer

Latest News

  1. Plus Therapeutics Shareholder Update: Transition Achieved in 2019; Poised for Expansion in 2020

    AUSTIN, Texas, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company") today issued the following Letter to Shareholders from Dr. Marc Hedrick, President and Chief Executive Officer.

  2. Plus Therapeutics Appoints Dr. An van Es-Johansson to Board of Directors

    AUSTIN, Texas, Jan. 02, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), today announced that Dr. An van Es-Johansson has joined the Company's Board of Directors to serve as an

  3. Plus Therapeutics to Present at Biotech Showcase 2020

    AUSTIN, Texas, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company") today announced that it has scheduled a company presentation at Biotech Showcase 2020, to be held January 13-15,

  4. Plus Therapeutics to Present at the LD Micro Main Event (XII)

    AUSTIN, Texas, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company") today announced that it will be participating at the upcoming 12th annual LD Micro Main Event.  Dr. Marc Hedrick,

  5. Plus Therapeutics Reports Third Quarter 2019 Financial and Business Results

    AUSTIN, Texas, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company") today announced financial and business results for the third quarter of 2019. Third quarter 2019 net income

  6. Plus Therapeutics To Report Fiscal 2019 Third Quarter Financial Results and Corporate Update on November 14, 2019

    AUSTIN, Texas, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company") today announced that it will report its Fiscal 2019 Third Quarter financial results after the close of market on

  7. Plus Therapeutics Receives $4.6MM Reimbursement Payment

    AUSTIN, Texas, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company") today announced that it received a $4.6 million payment from the U.S. Department of Health and Human Services /

  8. Plus Therapeutics, Inc. Announces Closing of $15 Million Underwritten Public Offering

    AUSTIN, Texas, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company") today announced the closing of its previously announced underwritten public offering (the "Offering") of 3,000,000

  9. Plus Therapeutics, Inc. Announces Pricing Of $15 Million Underwritten Public Offering

    AUSTIN, Texas, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company") today announced the pricing of an underwritten public offering (the "Offering") of 3,000,000 units, each unit

  10. Plus Therapeutics to Receive $4.6MM Reimbursement Payment

    AUSTIN, Texas, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company") today announced that it received notice from the U.S. Department of Health and Human Services / Office of the